IRIS
INNAO, Vanessa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.692
NA - Nord America 2.963
AS - Asia 1.765
SA - Sud America 534
AF - Africa 59
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 3
Totale 9.021
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.895
RU - Federazione Russa 1.812
SG - Singapore 754
BR - Brasile 466
CN - Cina 438
IE - Irlanda 427
IT - Italia 371
SE - Svezia 355
PL - Polonia 218
HK - Hong Kong 174
DE - Germania 124
FR - Francia 113
VN - Vietnam 111
IN - India 65
HU - Ungheria 61
GB - Regno Unito 51
FI - Finlandia 37
BD - Bangladesh 29
CA - Canada 27
ID - Indonesia 27
MX - Messico 26
AR - Argentina 23
BE - Belgio 22
IQ - Iraq 21
JP - Giappone 20
TR - Turchia 20
AT - Austria 19
NL - Olanda 19
PK - Pakistan 17
ZA - Sudafrica 17
ES - Italia 13
UA - Ucraina 13
EG - Egitto 12
MA - Marocco 12
LT - Lituania 10
PH - Filippine 10
VE - Venezuela 10
AZ - Azerbaigian 8
EC - Ecuador 8
KR - Corea 8
SA - Arabia Saudita 7
UZ - Uzbekistan 7
CL - Cile 6
CZ - Repubblica Ceca 6
MY - Malesia 6
TW - Taiwan 6
BO - Bolivia 5
JO - Giordania 5
KE - Kenya 5
PE - Perù 5
PS - Palestinian Territory 5
RO - Romania 5
CO - Colombia 4
NI - Nicaragua 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
KG - Kirghizistan 3
NP - Nepal 3
PY - Paraguay 3
SK - Slovacchia (Repubblica Slovacca) 3
UY - Uruguay 3
XK - ???statistics.table.value.countryCode.XK??? 3
AU - Australia 2
BH - Bahrain 2
DO - Repubblica Dominicana 2
EU - Europa 2
IL - Israele 2
JM - Giamaica 2
KZ - Kazakistan 2
LY - Libia 2
MN - Mongolia 2
OM - Oman 2
RS - Serbia 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
AO - Angola 1
BG - Bulgaria 1
BY - Bielorussia 1
CH - Svizzera 1
CR - Costa Rica 1
DK - Danimarca 1
DZ - Algeria 1
ET - Etiopia 1
GE - Georgia 1
GP - Guadalupe 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
IR - Iran 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PR - Porto Rico 1
Totale 9.018
Salva come PNG Salva come JPEG
Città #
Ashburn 592
Moscow 528
Singapore 439
Dublin 427
Chandler 384
Dallas 343
Nyköping 228
Warsaw 212
Hong Kong 173
Messina 165
Beijing 143
San Jose 139
The Dalles 87
Princeton 76
Los Angeles 73
Medford 64
Ann Arbor 63
Budapest 59
Lauterbourg 59
Munich 50
New York 48
Des Moines 47
Jacksonville 42
Dearborn 40
São Paulo 39
Frankfurt am Main 32
Ho Chi Minh City 29
Buffalo 28
Dong Ket 25
Council Bluffs 24
Hanoi 23
Santa Clara 23
Tianjin 23
Brussels 22
Redondo Beach 21
Milan 20
Rio de Janeiro 20
Boardman 18
Cambridge 18
Chennai 18
Nuremberg 18
Wilmington 18
Jakarta 17
Rome 17
Tokyo 17
Belo Horizonte 16
Brooklyn 16
Jinan 16
Turku 16
Woodbridge 16
Nanjing 14
Orem 14
Chicago 13
Houston 13
Hangzhou 12
Pune 12
Vienna 12
Bremen 11
Guangzhou 11
Montreal 11
Hebei 10
Johannesburg 10
Cairo 9
Denver 9
London 8
Ningbo 8
Palermo 8
Paris 8
Porto Alegre 8
San Francisco 8
San Mateo 8
Seattle 8
Shanghai 8
Zhengzhou 8
Baku 7
Boston 7
Brasília 7
Lahore 7
Shenyang 7
Helsinki 6
Hillsboro 6
Istanbul 6
Manchester 6
Mexico City 6
Osasco 6
Poplar 6
Redwood City 6
Stockholm 6
Tashkent 6
Toronto 6
Amman 5
Atlanta 5
Baghdad 5
Belém 5
Bengaluru 5
Casablanca 5
Curitiba 5
Fortaleza 5
Fuzhou 5
Guarulhos 5
Totale 5.423
Salva come PNG Salva come JPEG
Nome #
Altered Microrna Expression Profile in the peripheral Lymphomonocytes of Multiple Myeloma Patients with Bisphosphonate-Induced Osteonecrosis of the Jaw 299
Diagnostic utility of Sudoscan for detecting Bortezomib-induced painful neuropathy 253
A multivariate analysis of Multiple Myeloma subtype plasma cells 248
SIRT1 and SIRT2 Expression correlates with advanced disease and bone lesions in Multiple Myeloma 241
Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw 234
Altered Long Noncoding RNA Expression Profile in Multiple Myeloma Patients with Bisphosphonate-Induced Osteonecrosis of the Jaw 216
Corneal Structural Changes in Nonneoplastic and Neoplastic Monoclonal Gammopathies 201
Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells 198
Disappearance of Acquired Hemophilia A after Complete Remission in a Multiple Myeloma Patient. 194
Evaluation of the AGE/sRAGE Axis in Patients with Multiple Myeloma 191
A rare spinal localization of gray zone lymphoma without mediastinal involvement: A case report and review of literature 189
Anticancer Activity of Curcumin and Its Analogues: Preclinical and Clinical Studies 188
Efficacia della chemioterapia convenzionale ad alte dosi in un caso di mieloma multiplo IgM primitivamente doppio-refrattario ai nuovi farmaci 181
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant 176
Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study 175
Changes in serum interleukin-8 and sRAGE levels in multiple myeloma patients 172
Vaccination of multiple myeloma: Current strategies and future prospects 171
Antiresorptive Agents and Anti-Angiogenesis Drugs in the Development of Osteonecrosis of the Jaw. 169
Tumor Circulating Plasma Cells Detected By Flow Cytometric Single Platform Method Correlate with Clinical Response to Therapy and Unfavorable Patiets’ Characteristics 167
Feasibility, Tolerability and Efficacy of Carfilzomib, Lenalidomide and Desamethasone (KRD) in Relapsed Refractory Myeloma Patients: A Real-Life Survey of the Sicilian Myeloma Network 165
Telomerase and telomere biology in hematological diseases: A new therapeutic target 164
Impact of Cumulative Dose of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real Life Survey of the Sicilian Myeloma Network 164
Myeloma cells induce the accumulation of activated CD94low NK cells by cell-to-cell contacts involving CD56 molecules 161
IXAZOMIB WITH EITHER DEXAMETHASONE, CYCLOPHOSPHAMIDE-DEXAMETHASONE, THALIDOMIDE-DEXAMETHASONE OR BENDAMUSTINE-DEXAMETHASONE FOLLOWED BY IXAZOMIB MAINTENANCE IN ELDERLY NEWLY DIAGNOSED MYELOMA PATIENTS 157
Vaccination strategies in lymphoproliferative disorders: Failures and successes 153
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib 153
The cancer stem cell hypothesis: a guide to potential molecular targets. 150
Standardisation of minimal residual disease in multiple myeloma 150
A rare pancreatic pseudoaneurysm in patient with acute pancreatitis and multiple myeloma 144
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network 143
Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma. 140
Role of the microbiota in hematologic malignancies. 138
The metabolomic signature of hematologic malignancies 137
Antitumorigenic action of nelfinavir: Effects on multiple myeloma and hematologic malignancies (Review) 136
Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies 132
The adipose organ and multiple myeloma: Impact of adipokines on tumor growth and potential sites for therapeutic intervention 129
Extramedullary plasmacytoma of the maxilla simulating a maxillary radicular cyst: Quick diagnosis and management 124
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. 119
Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials 117
Diagnostic utility of Sudoscan for detecting bortezomib-induced painful neuropathy: a study on 18 patients with multiple myeloma 114
Quantitative polymerase Chain reaction profiling of microRNAs in peripheral lymph-monocytes from MGUS subjects 112
Post-chemotherapy cognitive impairment in hematological patients: current understanding of chemobrain in hematology 111
Nanobodies and Cancer: Current Status and New Perspectives 109
Preliminary Results of a Prospective Observational Study to Assess the Prevalence of Gaucher Disease in an Adult Population Affected By MGUS. 109
SIRT2 and SIRT3 expression correlates with redox imbalance and advanced clinical stage in patients with multiple myeloma 108
Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. 102
Immune thrombocytopenia: options and new perspectives 101
Formaldehyde exposure and acute myeloid leukemia: A review of the literature 97
Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosphamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age 97
Mitochondria-targeted antioxidant SkQ1 for gammopathy-related corneal damage 95
The ST2/interleukin-33 axis in hematologic malignancies: The IL-33 paradox 94
Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma 93
Lenalidomide maintenance with or without prednisone in newly diagnosed myeloma patients: A pooled analysis 90
Therapeutic potential of antagomiRs in haematological and oncological neoplasms 87
New insights into yes-associated protein signaling pathways in hematological malignancies: Diagnostic and therapeutic challenges 87
Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma 83
Potential Role of microRNAs in inducing Drug Resistance in Patients with Multiple Myeloma 83
Selective Inhibitors of Nuclear Export in the Treatment of Hematologic Malignancies 81
Oncolytic viruses and hematological malignancies: A new class of immunotherapy drugs 77
Radioprotective agents and enhancers factors. Preventive and therapeutic strategies for oxidative induced radiotherapy damages in hematological malignancies 77
New orally active proteasome inhibitors in multiple myeloma. 74
Reduced IL-33 plasma levels in multiple myeloma patients are associated with more advanced stage of disease 72
Relationship between mitofusin 2 and cancer. 70
Reviewing the significance of vitamin d substitution in monoclonal gammopathies 70
Immune checkpoint inhibitors in multiple myeloma: A review of the literature 65
New frontiers about the role of human microbiota in immunotherapy: The immune checkpoint inhibitors and CAR T-cell therapy era 65
Promising anti-mitochondrial agents for overcoming acquired drug resistance in multiple myeloma 52
null 19
Totale 9.233
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.690
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.690
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202142 0 0 0 0 0 0 0 0 0 0 0 42
2021/2022486 4 25 8 22 14 11 27 19 22 96 39 199
2022/20231.278 119 135 65 120 65 123 9 70 505 11 35 21
2023/2024335 22 75 28 26 29 62 2 20 1 17 7 46
2024/20251.557 83 32 21 89 91 73 36 243 402 96 173 218
2025/20264.554 231 284 373 249 409 874 624 582 594 216 57 61
Totale 9.233